| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PAICS |
| Uniprot No | P22234 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-425aa |
| 氨基酸序列 | MGSSHHHHHH SSGLVPRGSH MGSMATAEVL NIGKKLYEGK TKEVYELLDS PGKVLLQSKD QITAGNAARK NHLEGKAAIS NKITSCIFQLLQEAGIKTAF TRKCGETAFI APQCEMIPIE WVCRRIATGS FLKRNPGVKE GYKFYPPKVE LFFKDDANND PQWSEEQLIA AKFCFAGLLI GQTEVDIMSH ATQAIFEILE KSWLPQNCTL VDMKIEFGVD VTTKEIVLAD VIDNDSWRLW PSGDRSQQKD KQSYRDLKEV TPEGLQMVKK NFEWVAERVE LLLKSESQCR VVVLMGSTSD LGHCEKIKKA CGNFGIPCEL RVTSAHKGPD ETLRIKAEYE GDGIPTVFVA VAGRSNGLGP VMSGNTAYPV ISCPPLTPDW GVQDVWSSLR LPSGLGCSTV LSPEGSAQFA AQIFGLSNHL VWSKLRASIL NTWISLKQAD KKIRECNL |
| 预测分子量 | 50 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于PAICS重组蛋白研究的代表性文献摘要(模拟虚构内容，供参考格式)：
---
1. **文献名称**：Structural and functional analysis of human PAICS in purine biosynthesis
**作者**：Smith J, et al.
**期刊**：Nature Structural & Molecular Biology, 2018
**摘要**：通过重组表达人源PAICS蛋白并进行X射线晶体学分析，揭示了其双功能酶结构域的空间构象，阐明了其在嘌呤合成中的催化机制，为靶向PAICS的抗癌药物设计提供结构基础。
2. **文献名称**：PAICS as a novel oncogenic driver in pancreatic cancer
**作者**：Li X, Wang Y, et al.
**期刊**：Cancer Research, 2020
**摘要**：研究通过重组PAICS蛋白体外实验证实其促进胰腺癌细胞增殖和侵袭的分子机制，发现PAICS通过调控ATP代谢和EMT通路驱动肿瘤进展，提示其作为治疗靶点的潜力。
3. **文献名称**：High-yield expression and purification of recombinant PAICS for biochemical assays
**作者**：Kumar R, Gupta S
**期刊**：Protein Expression and Purification, 2019
**摘要**：优化大肠杆菌系统中PAICS重组蛋白的可溶性表达条件，建立镍柱亲和层析结合尺寸排阻色谱的两步纯化法，获得高纯度蛋白用于酶动力学和抑制剂筛选研究。
---
注：以上文献为示例性质，实际研究中请通过PubMed或Web of Science以"PAICS recombinant protein"等关键词检索最新论文。真实文献需包括DOI或PMID编号以便溯源。
PAICS (phosphoribosylaminoimidazole carboxylase and phosphoribosylaminoimidazolesuccinocarboxamide synthase) is a bifunctional enzyme encoded by the *PAICS* gene, playing a critical role in the *de novo* purine biosynthesis pathway. This pathway is essential for cellular proliferation, as purines serve as building blocks for DNA/RNA synthesis and energy metabolism. PAICS catalyzes two sequential steps in the formation of inosine monophosphate (IMP), the central precursor of purine nucleotides: the carboxylation of phosphoribosylaminoimidazole (CAIR) to phosphoribosylaminoimidazole carboxylase (SAICAR) and the subsequent succinocarboxamide formation. Its dual enzymatic activity is mediated by distinct carboxylase and synthetase domains within a single polypeptide.
Recombinant PAICS protein is produced via heterologous expression systems, such as *E. coli* or mammalian cell cultures, enabling precise study of its structure, function, and interactions. Research highlights PAICS overexpression in multiple cancers (e.g., breast, prostate, lung), where it supports rapid tumor growth by fueling nucleotide demand. Its oncogenic role extends beyond metabolism; PAICS interacts with signaling pathways (e.g., MYC, HIF-1α) and promotes epithelial-mesenchymal transition, metastasis, and chemoresistance. These findings position PAICS as a potential therapeutic target, spurring interest in inhibitors to disrupt purine synthesis in cancer cells.
Additionally, PAICS has implications in inflammatory and developmental disorders. Structural studies of recombinant PAICS reveal conformational dynamics critical for catalysis, informing drug design. Despite progress, challenges remain in understanding tissue-specific regulation and off-target effects of PAICS inhibition. Overall, recombinant PAICS tools are vital for dissecting its biological roles and advancing targeted therapies.
×
